13.89
price down icon1.42%   -0.20
after-market アフターアワーズ: 13.89
loading
前日終値:
$14.09
開ける:
$14.13
24時間の取引高:
1.53M
Relative Volume:
1.05
時価総額:
$2.22B
収益:
$340.81M
当期純損益:
$-419.65M
株価収益率:
-4.8737
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
-4.54%
1か月 パフォーマンス:
-2.80%
6か月 パフォーマンス:
-35.24%
1年 パフォーマンス:
-35.09%
1日の値動き範囲:
Value
$13.57
$14.13
1週間の範囲:
Value
$13.57
$14.88
52週間の値動き範囲:
Value
$10.57
$33.33

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name
名前
Denali Therapeutics Inc
Name
セクター
Healthcare (1174)
Name
電話
(650) 866-8547
Name
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Name
職員
443
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
DNLI's Discussions on Twitter

DNLI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
DNLI
Denali Therapeutics Inc
13.89 2.22B 340.81M -419.65M -402.10M -2.85
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-10 アップグレード Cantor Fitzgerald Neutral → Overweight
2025-03-07 再開されました Morgan Stanley Overweight
2025-02-11 開始されました Deutsche Bank Buy
2025-01-07 開始されました Robert W. Baird Outperform
2025-01-03 開始されました William Blair Outperform
2024-12-16 アップグレード Stifel Hold → Buy
2024-10-10 再開されました Raymond James Mkt Perform
2024-10-07 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-12-13 開始されました Citigroup Buy
2023-11-20 再開されました JP Morgan Overweight
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-09-06 開始されました B. Riley Securities Buy
2023-01-30 開始されました SVB Securities Outperform
2022-12-05 開始されました Cowen Outperform
2022-11-02 アップグレード BTIG Research Neutral → Buy
2022-11-02 開始されました BofA Securities Buy
2022-06-23 開始されました Berenberg Buy
2021-12-10 再開されました Raymond James Mkt Perform
2021-09-21 開始されました Oppenheimer Outperform
2021-09-01 開始されました SMBC Nikko Outperform
2021-05-18 開始されました UBS Buy
2021-02-26 繰り返されました H.C. Wainwright Buy
2021-02-10 アップグレード Cantor Fitzgerald Neutral → Overweight
2020-11-11 繰り返されました H.C. Wainwright Buy
2020-10-16 ダウングレード BTIG Research Buy → Neutral
2020-09-14 再開されました JP Morgan Overweight
2020-08-20 繰り返されました H.C. Wainwright Buy
2020-03-13 アップグレード Evercore ISI In-line → Outperform
2020-02-28 アップグレード Wedbush Neutral → Outperform
2020-02-24 開始されました Jefferies Buy
2020-02-19 開始されました Stifel Hold
2020-01-27 アップグレード Goldman Neutral → Buy
2019-09-26 開始されました Wedbush Neutral
2019-09-13 開始されました Nomura Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-26 開始されました H.C. Wainwright Buy
2018-11-15 開始されました Cantor Fitzgerald Overweight
2018-11-12 開始されました Janney Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-01-02 開始されました Evercore ISI Outperform
2018-01-02 開始されました Goldman Neutral
2018-01-02 開始されました JP Morgan Overweight
2018-01-02 開始されました Morgan Stanley Overweight
すべてを表示

Denali Therapeutics Inc (DNLI) 最新ニュース

pulisher
Jun 13, 2025

(DNLI) Investment Analysis - news.stocktradersdaily.com

Jun 13, 2025
pulisher
Jun 10, 2025

Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener

Jun 10, 2025
pulisher
Jun 09, 2025

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Has $341,000 Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

15,100 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Two Sigma Advisers LP - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

Denali Therapeutics Enters Registration Rights Agreement - TipRanks

Jun 03, 2025
pulisher
Jun 01, 2025

(DNLI) On The My Stocks Page - news.stocktradersdaily.com

Jun 01, 2025
pulisher
May 31, 2025

Q2 EPS Estimate for Denali Therapeutics Boosted by Analyst - Defense World

May 31, 2025
pulisher
May 30, 2025

Nuveen Asset Management LLC Sells 360,243 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

May 30, 2025
pulisher
May 29, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com Australia

May 29, 2025
pulisher
May 28, 2025

Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Bank of America Corp DE Trims Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

May 28, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target By Investing.com - Investing.com UK

May 27, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Sells 11,682 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

May 27, 2025
pulisher
May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025
pulisher
May 26, 2025

Millennium Management LLC Acquires 344,056 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

May 26, 2025
pulisher
May 21, 2025

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com

May 20, 2025
pulisher
May 19, 2025

Denali Therapeutics (DNLI) Receives a Price Target Adjustment fr - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Denali Therapeutics (DNLI) Receives a Price Target Adjustment from B of A Securities | DNLI Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by Analyst | DN - GuruFocus

May 19, 2025
pulisher
May 15, 2025

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Buy” from Analysts - Defense World

May 15, 2025
pulisher
May 13, 2025

Denali Therapeutics shares fall after price target cut to $32 By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 12, 2025

HC Wainwright Issues Optimistic Estimate for DNLI Earnings - Defense World

May 12, 2025
pulisher
May 11, 2025

Where are the Opportunities in (DNLI) - news.stocktradersdaily.com

May 11, 2025
pulisher
May 11, 2025

Q1 Earnings Forecast for DNLI Issued By Wedbush - Defense World

May 11, 2025
pulisher
May 08, 2025

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN

May 08, 2025
pulisher
May 08, 2025

Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics (DNLI) Price Target Reduced to $30 by Analys - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics shares fall after price target cut to $32 - Investing.com

May 08, 2025
pulisher
May 08, 2025

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics (DNLI) Price Target Revised Amid Strategic D - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks

May 08, 2025
pulisher
May 07, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwrigh - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks

May 07, 2025
pulisher
May 07, 2025

Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus

May 07, 2025
pulisher
May 06, 2025

Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 06, 2025
pulisher
May 06, 2025

Denali Therapeutics Reports First Quarter 2025 Financial - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan

May 06, 2025
pulisher
May 05, 2025

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView

May 05, 2025
pulisher
May 01, 2025

Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus

May 01, 2025
pulisher
Apr 22, 2025

First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq

Apr 22, 2025
pulisher
Apr 15, 2025

(DNLI) Technical Data - news.stocktradersdaily.com

Apr 15, 2025
pulisher
Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma - The Globe and Mail

Apr 10, 2025
pulisher
Apr 07, 2025

Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live

Apr 07, 2025
pulisher
Apr 05, 2025

Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com Australia

Apr 05, 2025

Denali Therapeutics Inc (DNLI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Denali Therapeutics Inc (DNLI) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ho Carole
Chief Medical Officer
Jan 07 '25
Sale
20.81
2,907
60,495
175,673
Schuth Alexander O.
COFO and Secretary
Jan 06 '25
Sale
20.22
12,255
247,796
247,215
Schuth Alexander O.
COFO and Secretary
Jan 07 '25
Sale
20.81
2,907
60,495
244,308
Watts Ryan J.
President and CEO
Jan 06 '25
Sale
20.22
29,266
591,759
260,721
Watts Ryan J.
President and CEO
Jan 07 '25
Sale
20.81
7,650
159,196
253,071
Krognes Steve E.
Director
Jan 07 '25
Sale
20.81
3,339
69,485
25,757
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
大文字化:     |  ボリューム (24 時間):